A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1 Study Evaluating the Safety of ABT-263 in Combination with Etoposide/Cisplatin in Subjects with Small Cell Lung Cancer (SCLC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

NCT00445198

Small Cell Lung Cancer Small Cell Lung Carcinoma

COMPLETED PHASE1/PHASE2

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00716534

Advanced or Metastatic Non-Small Cell Lung Cancer

COMPLETED PHASE2

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT01642251

Extensive Stage Small Cell Lung Carcinoma Large Cell Lung Carcinoma Neuroendocrine Carcinoma +2 more

COMPLETED PHASE1/PHASE2

Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

NCT00061646

Carcinoma, Non-Small-Cell Lung

TERMINATED PHASE2

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

NCT00043927

Small Cell Lung Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ABT-263 + etoposide/cisplatin

Group Type EXPERIMENTAL

ABT-263

Intervention Type DRUG

150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.

etoposide/cisplatin

Intervention Type DRUG

etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ABT-263

150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.

Intervention Type DRUG

etoposide/cisplatin

etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be greater then or equal to18 years of age;
* For dose escalation subject must have histologically and/or cytologically documented cancer for which etoposide/cisplatin has been determined to be an appropriate therapy. For expanded safety cohort subject must have histologically and/or cytologically documented SCLC for which etoposide/cisplatin has been determined an appropriate therapy;
* Subject has an ECOG performance score of less then or equal to 1; Evaluable and/or measurable disease by CT or MRI per RECIST criteria;
* Subjects with brain metastases must have clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function and no evidence of CNS disease progression as determined by CT or MRI within 21 days prior to the 1st dose of study drug;
* Must have adequate renal and hepatic function, per local laboratory reference range at Screening as follows:

* ANC greater then or equal to 1500/mcL,
* Platelets greater then or equal to 150,000/mm\^3,
* Hemoglobin greater then or equal to 10.0 g/dL,
* Serum creatinine less then or equal to 1.5 mg/dL or calculated creatinine clearance greater then or equal to 50 mL/min; Na greater then 130 mmol/L,
* Alkaline Phosphatase, AST and ALTless then or equal to 2.5 x ULN ;Bilirubin less then or equal to 1.5 x ULN.Subjects with liver mets may have ALP, AST and ALT less then or equal to 5.0 x ULN, Subjects with bone mets may have Alkaline Phosphatase less then or equal to 5.0 x ULN,
* Subjects with Gilbert's Syndrome may have a Bilirubin greater then 1.5 x ULN,
* Coagulation: aPTT, PT, less then or equal to 1.2 x ULN;
* Life expectancy of at least 30 days;
* Female subjects must be surgically sterile, postmenopausal (for at least 1 year), or have negative results for a pregnancy test;
* Female subjects not surgically sterile or postmenopausal (for at least one year) and non-vasectomized male subjects must practice at least one method of birth control.

Exclusion Criteria

* Subject exhibits evidence of other uncontrolled condition(s) including, but not limited to: active systemic infection, diagnosis of fever or neutropenia within 1 week of 1st dose;
* Subject has an underlying, predisposing condition of bleeding or currently exhibits signs of bleeding;
* Subject is currently receiving or requires anticoagulation therapy;
* Subject has active immune thrombocytopenic purpura, autoimmune hemolytic anemia or a history of being refractory to platelet transfusions (within 1 year prior to 1st dose of study drug);
* Subject has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis;
* Subject has a significant history of CV disease, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease;
* Female subject is pregnant or breast-feeding;
* Subject has tested positive for HIV;
* Subject has a history of other active malignancies within 3 years prior to study entry, with the exception of: adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the skin, previous malignancy confined and surgically resected with curative intent;
* Subject has received any anti-cancer therapy within 14 days prior to 1st dose of study drug;
* Subject has received steroid therapy for anti-neoplastic intent within 7 days prior to 1st dose of study drug;
* Subject has received aspirin within 7 days prior to 1st dose of study drug;
* Subject has received radio-immunotherapy within 6 months prior to 1st dose of study drug; Subject has received an antibody therapy or other biologics (with the exception of colony stimulating factors \[G-CSF,GM-CSF\] or erythropoietin) within 28 days prior to 1st dose of study drug;
* Subject has a hypersensitivity to platinum-containing compounds or etoposide;
* Subject has consumed grapefruit within 3 days prior to 1st dose of study drug.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No